You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

CYBORD+DARA

Cancer Type: Hematologic, Multiple Myeloma      Intent: Palliative
Regimen Category: Evidence-informed
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets

You might also be interested in